Rivaroxaban: A novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions

Annals of the New York Academy of Sciences

Volumn 1291, Issue 1, 2013, Pages 42-55

  Sarich, Troy C ^a   Peters, Gary ^a   Berkowitz, Scott D ^b   Misselwitz, Frank ^c   Nessel, Christopher C ^a   Burton, Paul ^a   Cook Bruns, Nancy ^c   Lensing, Anthonie W A ^c   Haskell, Lloyd ^a   Perzborn, Elisabeth ^c   Kubitza, Dagmar ^c   Moore, Kenneth T ^a   Jalota, Sanjay ^a   Weber, Juergen ^c   Pan, Guohua ^a   Sun, Xiang ^a   Westermeier, Torsten ^c   Nadel, Andrea ^b   Oppenheimer, Leonard ^a   Dibattiste, Peter M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Acute coronary syndromes; Atrial fibrillation; Deep vein thrombosis; Oral anticoagulant; Pulmonary embolism; Thromboembolic disease

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FIBRIN; FIBRINOGEN; FONDAPARINUX; HEPARIN; PLACEBO; PROTHROMBIN; RIVAROXABAN; THROMBIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; STEADY STATE; THERAPY EFFECT; THROMBOCYTE ACTIVATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84880509860     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12136     Document Type: Article

References (70)

1. Ansell, J., J. Hirsh, E. Hylek, et al. 2008. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 160S-198S.
2. Hirsh, J., T.E. Warkentin, R. Raschke, et al. 1998. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114: 489S-510S.
3. Misselwitz, F., S.D. Berkowitz & E. Perzborn. 2011. The discovery and development of rivaroxaban. Ann. N.Y. Acad. Sci. 1222: 64-75.
4. Perzborn, E., S. Roehrig, A. Straub, et al. 2011. The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor. Nat. Rev. Drug Discov. 10: 61-75.
5. Perzborn, E., J. Strassburger, A. Wilmen, et al. 2005. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. 3: 514-521.
6. Roehrig, S., A. Straub, J. Pohlmann, et al. 2005. Discovery of the novel antithrombotic agent 5-chloro-N-([(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl]methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct Factor Xa inhibitor. J. Med. Chem. 48: 5900-5908.
7. Kubitza, D. & S. Haas. 2006. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs 15: 843-855.
8. Mueck, W., A.W. Lensing, G. Agnelli, et al. 2011. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet. 50: 675-686.
9. Kubitza, D., M. Becka, B. Voith, et al. 2005. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin. Pharmacol. Ther. 78: 412-421.
10. Kubitza, D., M. Becka, G. Wensing, et al. 2005. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61: 873-880.
11. Kubitza, D., M. Becka, A. Roth, et al. 2008. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin. 24: 2757-2765.
12. Weinz, C., T. Schwarz, D. Kubitza, et al. 2009. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab. Dispos. 37: 1056-1064.
13. Eriksson, B.I., L. Borris, O.E. Dahl, et al. 2006. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 4: 121-128.
14. Eriksson, B.I., L.C. Borris, O.E. Dahl, et al. 2006. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114: 2374-2381.
15. Eriksson, B.I., L.C. Borris, O.E. Dahl, et al. 2007. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Res. 120: 685-693.
16. Turpie, A.G.G., W.D. Fisher, K.A. Bauer, et al. 2005. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost. 3: 2479-2486.
17. Eriksson, B.I., A.K. Kakkar, A.G.G. Turpie, et al. 2009. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J. Bone Joint Surg. Br. 91: 636-644.
18. Eriksson, B.I., L.C. Borris, R.J. Friedman, et al. 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358: 2765-2775.
19. Kakkar, A.K., B. Brenner, O.E. Dahl, et al. 2008. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372: 31-39.
20. Lassen, M.R., W. Ageno, L.C. Borris, et al. 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358: 2776-2786.
21. Turpie, A.G.G., M.R. Lassen, B.L. Davidson, et al. 2009. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373: 1673-1680.
22. Turpie, A.G.G., M.R. Lassen, B.I. Eriksson, et al. 2011. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 105: 444-453.
23. Heit, J.A., W.M. O'Fallon, T.M. Petterson, et al. 2002. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch. Intern. Med. 162: 1245-1248.
24. Spencer, F.A., C. Emery, D. Lessard, et al. 2006. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 21: 722-727.
25. White, R.H. 2003. The epidemiology of venous thromboembolism. Circulation 107: 14-18.
26. Cohen, A.T., G. Agnelli, F.A. Anderson, et al. 2007. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98: 756-764.
27. Lensing, A.W., P. Prandoni, M.H. Prins, et al. 1999. Deep-vein thrombosis. Lancet 353: 479-485.
28. Pengo, V., A.W. Lensing, M.H. Prins, et al. 2004. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350: 2257-2264.
29. Prandoni, P., A.W. Lensing, M.H. Prins, et al. 2004. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann. Intern. Med. 141: 249-256.
30. Goldhaber, S.Z. 1998. Pulmonary embolism. N. Engl. J. Med. 339: 93-104.
31. Weitz, J.I. & L.A. Linkins. 2007. Beyond heparin and warfarin: the new generation of anticoagulants. Expert Opin. Investig. Drugs 16: 271-282.
32. Kearon, C., S.R. Kahn, G. Agnelli, et al. 2008. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 454S-545S.
33. Brandjes, D.P., H. Heijboer, H.R. Büller, et al. 1992. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. 327: 1485-1489.
34. The EINSTEIN Investigators. 2010. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363: 2499-2510.
35. The EINSTEIN-PE Investigators. 2012. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366: 1287-1297.
36. Fiessinger, J.N., M.V. Huisman, B.L. Davidson, et al. 2005. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293: 681-689.
37. van Gogh Investigators, H.R., Büller, A.T., Cohen, et al. 2007. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 357: 1094-1104.
38. Agnelli, G., A. Gallus, S.Z. Goldhaber, et al. 2007. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116: 180-187.
39. Büller, H.R., A.W. Lensing, M.H. Prins, et al. 2008. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood 112: 2242-2247.
40. Buller, H.R. 2012. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Blood 120. Abstract 20.
41. Go, A.S., E.M. Hylek, K.A. Phillips, et al. 2001. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375.
42. Hart, R.G., O. Benavente, R. McBride, et al. 1999. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131: 492-501.
43. Camm, A.J., P. Kirchhof, G.Y.H. Lip, et al. 2010. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12: 1360-1420.
44. Fuster, V., L.E. Rydén, D.S. Cannom, et al. 2006. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354.
45. Guyatt, G.H., E.A. Akl, M. Crowther, et al. 2012. Executive summary: antithrombotic therapy and prevention, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141: 7S-47S.
46. Patel, M.R., K.W. Mahaffey, J. Garg, et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365: 883-891.
47. Fuster, V., L.E. Rydén, R.W. Asinger, et al. 2001. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 22: 1852-1923.
48. Turpie, A.G.G. & C. Esmon. 2011. Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation. Thromb. Haemost. 105: 586-596.
49. Watson, T., E. Shantsila & G.Y.H. Lip. 2009. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 373: 155-166.
50. ROCKET AF Study Investigators. 2010. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159: 340-347.
51. Baker, W.L., D.A. Cios, S.D. Sander, et al. 2009. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15: 244-252.
52. Connolly, S.J., M.D. Ezekowitz, S. Yusuf, et al. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361: 1139-1151.
53. Granger, C.B., J.H. Alexander, J.J. McMurray, et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365: 981-992.
54. Rothberg, M.B., C. Celestin, L.D. Fiore, et al. 2005. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann. Intern. Med. 143: 241-250.
55. Gage, B.F., A.D. Waterman, W. Shannon, et al. 2001. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870.
56. Singer, D.E., G.W. Albers, J.E. Dalen, et al. 2008. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133: 546S-592S.
57. Cannon, C.P. & P. Kohli. 2012. Danger ahead: watch out for indirect comparisons! J. Am. Coll. Cardiol. 60: 747-748.
58. Hori, M., M. Matsumoto, N. Tanahashi, et al. 2012. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study. Circ. J. 76: 2104-2111.
59. Feinberg, W.M., J.L. Blackshear, A. Laupacis, et al. 1995. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155: 469-473.
60. Coleman, C.I., M.S. Roberts, D.M. Sobieraj, et al. 2012. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr. Med. Res. Opin. 28: 669-680.
61. Coleman, C.I., B. Limone, D.M. Sobieraj, et al. 2012. Dosing frequency and medication adherence in chronic disease. J. Manag. Care Pharm. 18: 527-539.
62. Go, A.S., D. Mozaffarian, V.L. Roger, et al. 2013. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
63. Mizukoshi, M., T. Imanishi, A. Tanaka, et al. 2010. Clinical classification and plaque morphology determined by optical coherence tomography in unstable angina pectoris. Am. J. Cardiol. 106: 323-328.
64. Kar, S. & D.L. Bhatt. 2012. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coron. Artery. Dis. 23: 380-390.
65. Coughlin, S.R. 2005. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3: 1800-1814.
66. Steg, P.G., S.K. James, D. Atar, et al. 2012. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33: 2569-2619.
67. Mega, J.L., E. Braunwald, S. Mohanavelu, et al. 2009. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374: 29-38.
68. Mega, J.L., E. Braunwald, S.D. Wiviott, et al. 2012. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366: 9-19.
69. Cohen, A.T., T.E. Spiro, H.R. Büller, et al. 2013. Rivaroxaban for thromboembolism in acutely ill medical patients. N. Engl. J. Med. 368: 513-523.
70. World Health Organization. Cardiovascular diseases (CVDs). 2012. Accessed January 11, 2013. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.